major
respiratori
tract
infect
rti
commun
acquir
singl
common
caus
physician
offi
ce
visit
among
common
caus
hospit
morbid
mortal
associ
rti
signifi
cant
fi
nancial
social
burden
high
due
lost
time
work
school
scope
clinic
symptom
signifi
cantli
overlap
among
respiratori
pathogen
sever
diseas
vari
depend
patient
age
underli
diseas
immun
statu
therebi
lead
inaccur
presumpt
diseas
etiolog
rapid
accur
diagnosi
caus
agent
rti
improv
patient
care
reduc
morbid
mortal
promot
effect
hospit
bed
util
antibiot
stewardship
reduc
length
stay
chapter
focus
clinic
util
advantag
disadvantag
viral
bacteri
test
clear
food
drug
administr
fda
new
promis
technolog
detect
bacteri
agent
pneumonia
current
develop
us
fda
clinic
trial
briefl
review
major
respiratori
tract
infect
rti
communityacquir
singl
common
caus
physician
offi
ce
visit
among
common
caus
hospit
morbid
mortal
associ
rti
signifi
cant
fi
nancial
social
burden
high
due
lost
time
work
school
viral
infect
caus
respiratori
tract
diseas
mix
viral
infect
present
viral
rti
adult
high
studi
children
year
age
europ
usa
incid
pneumonia
due
bacteri
pathogen
case
per
inhabit
depend
variou
factor
age
differenti
viral
bacteri
rti
assist
consid
rate
onset
ill
patient
age
symptom
radiograph
chang
biomark
respons
treatment
presenc
document
viral
epidem
commun
howev
scope
clinic
symptom
signifi
cantli
overlap
among
respiratori
pathogen
sever
diseas
vari
depend
patient
age
underli
diseas
immun
statu
therebi
lead
inaccur
presumpt
diseas
etiolog
numer
studi
demonstr
rapid
accur
diagnosi
caus
agent
rti
improv
patient
care
reduc
morbid
mortal
promot
effect
hospit
bed
util
antibiot
stewardship
reduc
length
stay
pathogen
etiolog
may
need
consid
clinic
manag
certain
patient
immunocompromis
patient
young
infant
potenti
develop
sever
diseas
health
care
set
identifi
cation
viral
rti
prompt
initi
appropri
infect
control
measur
therebi
reduc
morbid
mortal
associ
nosocomi
transmiss
last
sever
year
great
advanc
made
obtain
usa
food
drug
administr
fda
clearanc
varieti
nucleic
acid
amplifi
cation
test
naat
detect
singl
multipl
viral
respiratori
pathogen
three
bacteri
pathogen
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
chapter
focus
clinic
util
advantag
disadvantag
test
unfortun
fdaclear
assay
avail
detect
major
bacteri
fungal
pathogen
associ
communityacquir
pneumonia
cap
hospitalassoci
pneumonia
hap
ventilatorassoci
pneumonia
vap
new
promis
technolog
detect
bacteri
agent
pneumonia
current
develop
us
fda
clinic
trial
briefl
review
although
sensit
accur
fungal
diagnost
area
import
develop
new
diagnost
assay
signifi
cantli
delay
henc
detect
vast
major
nonvir
pathogen
laboratori
develop
test
ldt
mainstay
molecular
test
discuss
import
new
rapid
diagnost
cap
vap
hap
highlight
workshop
conduct
novemb
infecti
diseas
societi
america
idsa
collabor
fda
proceed
publish
special
supplement
clinic
infecti
diseas
idsa
execut
summari
workshop
state
need
develop
implement
modern
molecular
technolog
advanc
microbiolog
diagnost
test
common
virus
caus
lower
rti
lrti
upper
rti
urti
list
tabl
overal
virus
common
caus
urti
second
common
etiolog
caus
cap
behind
streptococcu
pneumonia
rang
diagnos
case
cap
children
predomin
viral
etiolog
major
infect
caus
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
human
metapneumoviru
hmpv
parainfl
uenza
virus
piv
infl
uenza
flua
infl
uenza
b
flub
adenoviru
adv
coronavirus
cov
addit
caus
cap
children
rti
nonimmun
compromis
hospit
children
especi
year
age
mainli
due
infect
one
multipl
virus
without
secondari
bacteri
infect
viral
cap
decreas
frequenc
healthi
young
middleag
adult
onethird
case
infl
uenza
hrv
cov
common
agent
viral
cap
rate
substanti
increas
among
elderli
often
complic
secondari
bacteri
infect
common
viral
caus
cap
elderli
infl
uenza
rsv
howev
hmpv
piv
cov
hrv
caus
urti
lrti
sinc
sever
cluster
respiratori
ill
associ
human
enteroviru
report
asia
europ
usa
mmwr
uniqu
enteroviru
similar
biolog
featur
hrv
associ
rti
rang
rel
mild
ill
sever
ill
requir
intens
care
mechan
ventil
sever
diseas
particularli
pronounc
children
mmwr
although
human
bocaviru
hbov
implic
caus
rti
major
case
hbov
detect
conjunct
viral
pathogen
clinic
signifi
canc
hbov
still
debat
hbov
commonli
found
children
howev
hbov
affect
person
age
underli
diseas
cancer
associ
sever
infect
requir
hospit
gener
cov
caus
mild
selflimit
urti
common
cold
howev
last
decad
two
covssever
acut
respiratori
syndrom
sarscov
middl
east
respiratori
syndrom
merscov
emerg
potenti
pandem
threat
due
persontoperson
communic
virus
caus
sever
lower
respiratori
tract
diseas
extrapulmonari
involv
associ
high
casefat
rate
although
sarscov
current
circul
sinc
merscov
continu
caus
outbreak
middl
east
secondari
spread
europ
africa
asia
north
america
preval
viral
pathogen
vari
depend
environment
condit
climat
season
geograph
locat
exampl
new
york
citi
area
adenoviru
adv
tend
circul
preval
year
round
fig
rsv
detect
sporad
year
round
peak
season
octob
februari
fig
unpublish
data
provid
author
classic
infl
uenza
season
begin
gener
late
octob
wane
april
hmpv
preval
tend
rise
rsv
season
wane
februari
peak
spring
preval
summer
fall
prevail
spring
fall
viru
preval
also
patient
popul
driven
eg
pediatr
adult
geriatr
outpati
inpati
exampl
rsv
hmpv
primarili
found
children
year
age
caus
sever
diseas
age
group
immunosuppress
popul
less
common
respiratori
viral
pathogen
herp
simplex
viru
hsv
cytomegaloviru
cmv
must
consid
potenti
caus
rti
major
bacteri
pathogen
respons
cap
haemophilu
infl
uenza
variabl
gramneg
rod
rare
neisseria
meningitidi
depend
patient
underli
diseas
chronic
obstruct
pulmonari
diseas
copd
asthma
moraxella
cattharali
gener
associ
otiti
media
children
exacerb
asthma
copd
adult
classic
atyp
pathogen
caus
cap
includ
c
pneumonia
pneumonia
legionella
pneumophila
also
nosocomi
acquir
institut
set
major
rti
caus
c
pneumonia
asymptomat
minim
symptom
c
pneumonia
account
cap
case
sinus
pharyng
tracheiti
bronchiol
bronchiti
exacerb
chronic
bronchiti
asthma
immunocompet
immunosuppress
person
c
pneumonia
present
bacteri
pathogen
adult
case
cap
c
pneumonia
infect
present
vari
clinic
cours
mild
selflimit
diseas
sever
form
pneumonia
particularli
patient
cardiopulmonari
diseas
elderli
age
group
affect
howev
c
pneumonia
infect
rare
found
young
children
year
age
howev
age
person
detect
antibodi
level
elderli
demonstr
seroposit
rate
pneumonia
estim
caus
case
cap
although
infect
asymptomat
mild
often
selflimit
approxim
infect
may
requir
hospit
lead
seriou
extrapulmonari
complic
lrti
common
school
age
children
adolesc
preval
pediatr
lrti
rang
pneumonia
infect
caus
outbreak
commun
institut
school
prison
hospit
legionella
spp
caus
two
distinct
clinic
entiti
pontiac
fever
selflimit
fl
ulik
ill
legionair
diseas
sever
multisystem
diseas
involv
pneumonia
case
sporad
part
outbreak
due
environment
exposur
l
pneumophila
respons
cap
respons
cap
requir
hospit
l
pneumophila
serogroup
respons
diagnos
diseas
probabl
major
diagnost
test
specifi
c
serogroup
risk
factor
contract
legionellosi
includ
smoke
immunosuppress
age
chronic
lung
diseas
emphysema
diabet
kidney
diseas
cancer
contact
environment
system
air
condit
cool
tower
evapor
condens
whirlpool
hot
spring
bath
coxiella
burnetii
oblig
gramneg
intracellular
bacterium
primari
reservoir
cattl
sheep
goat
transmiss
human
occur
primarili
inhal
aerosol
contamin
soil
anim
wast
c
burnetti
infect
manifest
q
fever
selflimit
infl
uenzalik
febril
ill
abrupt
onset
manifest
chill
headach
myalgia
fatigu
sweat
cdc
mmwr
howev
pneumonia
predomin
north
america
usual
mild
natur
patient
dyspnea
pleurit
chest
pain
dri
nonproduct
cough
rare
c
burnetti
infect
occasion
progress
acut
respiratori
distress
syndrom
ard
cdc
mmwr
b
pertussi
caus
whoop
cough
pertussislik
ill
attribut
bordetella
parapertussi
bordetella
holmseii
rare
bordetella
bronchioseptica
infect
overal
bordetella
infect
increas
dramat
last
year
due
wane
immun
incomplet
antibodi
respons
vaccin
acellular
vaccin
lack
vaccin
recent
epidem
occur
case
report
occur
california
nationwid
case
report
cdc
http
wwwcdcgovpertussi
survreportinghtml
highest
incid
note
infant
year
age
signifi
cant
amount
diseas
occur
among
children
age
year
one
larg
outbreak
pertussislik
ill
ohio
attribut
b
pertussi
case
b
holmseii
case
outbreak
pertussi
continu
highlight
need
primari
vaccin
administr
tdap
booster
immun
hap
vap
often
associ
drugresist
multidrugresist
panresist
bacteria
mrsa
extendedspectrum
betalactamas
esbl
produc
enterobacteriaca
carbapenemaseproduc
enterobacteriaca
pseudomona
spp
acinetobact
spp
stenotrophomona
maltophilia
patient
intens
care
unit
icu
immunocompromis
patient
pathogen
nocardia
spp
corynebacterium
spp
pneumocysti
jiroveci
fusarium
spp
aspergillu
spp
cryptococcu
spp
zygomycet
need
consid
differenti
diagnosi
convent
viru
detect
method
includ
rapid
antigen
detect
test
radt
direct
fl
uoresc
antibodi
test
dfa
rapid
cell
cultur
tradit
tube
cultur
although
method
accept
diagnost
tool
certain
clinic
set
often
inferior
breadth
pathogen
identifi
ed
assay
sensit
result
turnaround
time
compar
naat
sensit
specifi
citi
diagnost
test
particular
convent
test
highli
depend
viral
target
age
patient
durat
symptom
prior
sampl
collect
sampl
collect
method
transport
storag
condit
radt
gener
simplest
test
perform
mani
waiv
test
clinic
laboratori
improv
amend
clia
result
gener
avail
within
min
despit
benefi
ts
radt
limit
util
due
narrow
scope
pathogen
detect
rsv
flua
flub
modest
poor
sensit
rang
rsv
infl
uenza
virus
depend
compar
method
overal
specifi
citi
radt
good
howev
specifi
citi
detect
infl
uenza
signifi
cantli
lower
previous
report
radt
gener
perform
better
test
pediatr
sampl
sinc
children
shed
higher
titer
viru
longer
time
period
adult
especi
elderli
dfa
detect
broader
rang
virus
adv
flua
flub
hmpv
rsv
perform
min
sensit
dfa
vari
viru
rang
high
approxim
rsv
low
adv
compar
naat
dfa
gener
specifi
c
although
specifi
citi
depend
level
technic
expertis
reader
rapid
cell
cultur
quideldiagnost
hybrid
athen
oh
detect
adv
flua
flub
rsv
demonstr
sensit
rang
high
flua
strain
low
rsv
excel
specifi
citi
greater
compar
naat
rapid
cell
cultur
gener
posit
within
h
seven
virus
detect
depend
cell
line
use
antibodi
avail
confi
rmation
tradit
tube
cultur
broader
scope
pathogen
detect
compar
radt
dfa
rapid
cell
cultur
tradit
cultur
identifi
adv
enteroviru
ev
hmpv
flua
flub
rsv
hrv
plu
addit
virus
associ
lower
rti
immunocompromis
patient
includ
cmv
varicella
zoster
viru
vzv
often
laboratori
specifi
calli
screen
hrv
cultur
although
hrv
common
respiratori
viru
detect
shown
caus
signifi
cant
seriou
diseas
young
elderli
immunosuppress
patient
well
patient
underli
chronic
lung
diseas
copd
asthma
addit
mani
addit
import
virus
sarscov
merscov
potenti
hbov
caus
urti
lrti
routin
identifi
ed
tradit
cultur
final
due
timetovirusdetect
tradit
cultur
gener
day
respiratori
virus
week
slowgrow
virus
cmv
result
usual
avail
within
time
frame
h
could
affect
patient
manag
ie
initi
appropri
antivir
therapi
discontinu
inappropri
antibiot
therapi
summari
radt
dfa
rapid
cell
cultur
may
provid
result
within
clinic
relev
time
frame
limit
pathogen
scope
reduc
sensit
compar
naat
addit
radt
dfa
rapidtradit
cell
cultur
rare
detect
one
viru
singl
sampl
standard
method
detect
bacteri
pathogen
caus
pneumonia
gram
stain
combin
microbiolog
cultur
lower
respiratori
tract
specimen
blood
often
cultur
respiratori
specimen
order
hospit
patient
rare
perform
outpati
set
gram
stain
result
avail
within
hour
result
alway
correl
cultur
cultur
antibiot
suscept
result
usual
avail
day
sampl
collect
detect
rate
pathogen
rel
low
metaanalysi
evalu
report
cap
time
period
show
bacteri
pathogen
identifi
ed
sampl
test
urinari
antigen
test
pneumonia
offer
substanti
improv
cultur
sensit
specifi
citi
bacterem
adult
howev
nonbacterem
adult
children
sensit
specifi
citi
lower
falseposit
pneumonia
antigen
test
report
relat
antibiot
interfer
legionella
spp
identifi
ed
growth
buffer
charcoal
yeast
extract
agar
sensit
legionella
cultur
vari
signifi
cantli
dfa
sensit
urinari
antigen
test
l
pneumophila
improv
detect
suboptim
sinc
detect
limit
serogroup
l
pneumophila
serogroup
sensit
test
vari
laboratori
cultur
mycoplasma
chlamydophila
tradit
b
pertussi
identifi
ed
use
cultur
bordetgeng
media
andor
dfa
howev
sensit
cultur
rang
sensit
dfa
rang
addit
cultur
take
mani
day
therefor
naat
becom
gold
standard
rapid
sensit
identifi
cation
pertussi
serolog
antibodi
test
avail
respiratori
pathogen
provid
supplement
inform
howev
due
delay
develop
detect
igm
igg
antibodi
certain
pathogen
eg
l
pneumophila
c
pneumonia
b
pertussi
use
diagnosi
clinic
relev
time
frame
limit
shortcom
serolog
test
includ
time
serum
sampl
difficulti
obtain
appropri
pair
serum
sampl
high
background
igg
antibodi
preval
adult
popul
serolog
diagnosi
misinterpret
due
prior
immun
infect
case
infl
uenza
requir
demonstr
signifi
cant
rise
antibodi
titer
initi
convalesc
sampl
final
person
immun
suppress
may
develop
antibodi
may
insuffi
cient
level
detect
limit
function
serolog
monitor
vaccin
respons
epidemiolog
studi
determin
preval
rate
prior
flua
pandem
infecti
caus
cap
mostli
infer
base
clinic
present
highli
inaccur
sinc
bacteria
atyp
pathogen
mani
respiratori
virus
caus
ill
similar
clinic
symptom
one
studi
demonstr
physician
recogn
infl
uenza
hospit
children
nonhospit
children
laboratoryconfi
rmed
infl
uenza
diagnosi
base
clinic
symptom
diagnost
test
limit
radt
flua
flub
rsv
hospit
offer
comprehens
dfa
viral
cultur
laboratorydevelop
naat
superior
abil
naat
rapidli
accur
detect
known
novel
pathogen
best
exemplifi
ed
chao
flua
pandem
fortun
start
pandem
two
naat
fdaclear
detect
infl
uenza
virus
prodess
proflu
holog
san
diego
ca
detect
differenti
flua
flub
one
highli
multiplex
naat
luminex
xtag
rvp
respiratori
viru
panel
luminex
molecular
diagnost
toronto
canada
xtag
assay
enabl
laboratori
detect
flua
differenti
season
flua
season
flua
also
identifi
mani
circul
virus
shown
fig
number
sampl
posit
respiratori
viru
increas
dramat
use
highli
multiplex
xtag
rvp
assay
compar
tradit
test
method
includ
radt
dfa
rapid
cell
cultur
interestingli
mix
viral
infect
contain
four
viral
pathogen
identifi
ed
hospit
patient
similarli
studi
shown
broad
test
panel
use
one
viru
identifi
ed
respiratori
sampl
although
signific
mix
viral
infect
need
clearli
defi
ned
clinic
impact
need
consid
potenti
sever
patient
comorbid
immunosuppress
critic
ill
respiratori
viru
season
high
infl
uenza
rate
patient
pathogen
often
place
hospit
room
togeth
cohort
due
limit
privat
room
consequ
second
viral
infect
alreadi
serious
ill
hospit
patient
could
substanti
indic
comprehens
test
panel
essenti
set
consequ
major
shift
test
practic
numer
fdaclear
singleand
multianalyt
molecular
test
detect
respiratori
pathogen
becom
avail
tabl
viral
respiratori
pathogen
particularli
suit
detect
use
naat
sinc
number
target
rel
limit
detect
respiratori
viru
gener
consid
diagnost
although
asymptomat
carriag
certain
respiratori
virus
report
sever
studi
major
viral
atyp
bacteri
respiratori
pathogen
naat
offer
enhanc
sensit
cultur
radt
dfa
see
tabl
refer
specifi
citi
vari
target
assay
design
gener
high
naat
also
suit
detect
respiratori
pathogen
routin
easili
cultur
eg
c
pneumonia
pneumonia
hbov
hmpv
pathogen
danger
cultur
eg
sarscov
merscov
pathogen
timetodetect
tradit
test
often
delay
impact
patient
care
eg
infl
uenza
cmv
cell
cultur
expand
scope
pathogen
detect
previou
low
three
viral
pathogen
detect
radt
viral
three
bacteri
pathogen
detect
naat
greatli
enhanc
clinic
laboratori
diagnost
capabl
data
deriv
studi
util
comprehens
viral
bacteri
naat
continu
provid
invalu
insight
clinic
manifest
viral
bacteri
infect
signifi
canc
mix
viral
infect
surprisingli
realiz
virus
colon
host
without
overt
diseas
asid
use
radt
infl
uenza
season
rti
diagnost
test
includ
viral
dfa
cultur
bacteri
cultur
naat
serolog
test
atyp
pathogen
urinari
antigen
test
pneumonia
l
pneumophila
still
underutil
outpati
set
therefor
treatment
patient
cap
gener
empir
base
guidelin
american
thorac
societi
idsa
rather
confi
rmed
laboratori
diagnosi
antibiot
select
must
cover
preval
bacteri
pathogen
atyp
pathogen
despit
high
preval
viral
infect
approxim
million
million
antibiot
prescript
prescrib
viral
lower
upper
rti
despit
fact
bacteri
etiolog
highli
unlik
convers
identifi
cation
viral
pathogen
lead
administr
appropri
antivir
exampl
earli
week
infl
uenza
pandem
four
differ
infl
uenza
virus
circul
vari
antivir
suscept
pattern
accord
surveil
data
provid
center
diseas
control
prevent
cdc
atlanta
ga
strain
demonstr
resist
fi
rst
line
therapeut
oseltamivir
neuraminidas
inhibitor
suscept
adamantin
oseltamivirsuscept
adamantineresist
flua
oseltamivirsuscept
adamantineresist
flub
oseltamivirsuscept
adamantineresist
therefor
identifi
cation
specifi
c
strain
infl
uenza
viru
caus
infect
specifi
c
patient
essenti
ensur
proper
drug
select
especi
highrisk
critic
ill
patient
addit
appropri
use
infl
uenza
antivir
achiev
accur
rapid
diagnosi
made
recent
studi
demonstr
rapid
test
permit
time
administr
oseltamivir
allow
rapid
discontinu
treatment
person
without
document
infl
uenza
final
new
viral
therapeut
agent
respiratori
virus
infl
uenza
develop
andor
clinic
trial
proper
administr
new
agent
depend
laboratori
provid
accur
test
detect
broad
rang
viral
pathogen
hap
vap
initi
empir
therapi
choic
may
standard
initi
base
patient
clinic
statu
underli
diseas
andor
risk
infect
multidrugresist
pathogen
initi
therapi
often
inadequ
therebi
extend
cours
diseas
increas
morbid
mortal
hospit
length
stay
mortal
rate
icu
pneumonia
case
rang
initi
therapi
adequ
initi
therapi
inappropri
chang
cultur
result
obtain
furthermor
inadequ
andor
unnecessari
broad
spectrum
antibiot
therapi
enhanc
spread
drugresist
pathogen
within
institut
set
increas
risk
hospitalacquir
infect
clostridium
diffi
cile
mrsa
vancomycinresist
enterococci
comprehens
naat
provid
key
inform
antivir
therapi
select
also
aid
restrict
antibiot
use
circumst
antibiot
therapi
appropri
promot
switch
target
specifi
c
therapi
thu
reduc
use
broad
spectrum
antibiot
indic
practic
keep
goal
antibiot
stewardship
especi
consid
steadi
critic
rise
antibiot
resist
limit
option
avail
treatment
multidrug
panresist
bacteri
infect
burden
nosocomi
infect
signifi
cant
incur
addit
cost
supplement
diagnost
test
extend
hospit
increas
morbid
mortal
therefor
rapid
diagnost
test
need
identifi
infect
patient
upon
admiss
therebi
prevent
nosocomi
transmiss
facilit
isol
appropri
cohort
decis
studi
document
signifi
cant
nosocomi
transmiss
adv
infl
uenza
rsv
hmpv
piv
hrv
hospit
unit
chronic
care
facil
pediatr
unit
height
rsv
season
preval
high
number
hospit
admiss
often
requir
cohort
rsvposit
children
due
lack
privat
room
howev
limit
diagnost
test
rsv
alon
cohort
scenario
could
put
serious
ill
children
risk
acquisit
second
viral
infect
pathogen
hmpv
hrv
rapid
identifi
cation
health
care
facilityacquir
legionella
infect
essenti
environ
sourc
identifi
ed
erad
thu
prevent
transmiss
addit
pcr
techniqu
use
proactiv
routin
screen
potenti
environment
sourc
identifi
cation
wide
rang
viral
pathogen
essenti
epidemiolog
surveil
establish
season
popul
pattern
serv
excel
indic
predict
immun
schedul
eg
infl
uenza
administ
prevent
measur
eg
rsv
immun
globulin
previous
surveil
done
state
depart
health
nation
level
cdc
comprehens
naat
enabl
local
laboratori
monitor
real
time
viral
preval
provid
clinician
health
care
facil
regular
updat
circul
virus
test
decis
use
local
data
addit
resourc
epidemiolog
inform
provid
cdc
web
site
http
wwwcdcgovfl
u
studi
wong
et
al
demonstr
use
multiplex
naat
virus
identifi
ed
viru
outbreak
outbreak
specimen
neg
use
dfa
limit
number
individu
naat
ten
virus
overal
detect
rate
increas
outbreak
outbreak
specimen
comprehens
test
identifi
reemerg
new
emerg
viral
pathogen
case
infl
uenza
pandem
addit
naat
key
compon
understand
epidemiolog
featur
larg
outbreak
pertussislik
ill
exampl
larg
percentag
case
b
holmseii
identifi
ed
outbreak
ohio
contrast
previou
report
frequenc
detect
low
usa
seen
peak
pertussi
activ
everi
year
increas
case
sinc
accur
detect
pertussi
essenti
better
control
spread
diseas
public
health
standpoint
antimicrobi
prophylaxi
asymptomat
household
contact
children
less
year
age
pregnant
women
third
trimest
person
preexist
condit
risk
develop
sever
respiratori
failur
contact
highrisk
set
http
wwwcdcgovpertussisoutbreakspephtml
recoveri
respiratori
pathogen
highli
depend
use
appropri
sampl
type
collect
method
laboratori
use
commerci
fdaclear
assay
refer
manufactur
packag
inform
determin
sampl
type
valid
use
specifi
c
test
tabl
use
altern
sampl
type
permit
laboratori
perform
valid
studi
establish
accept
perform
characterist
test
altern
sampl
type
applic
upper
respiratori
tract
specimen
viral
c
pneumonia
pneumonia
test
includ
nasopharyng
np
wash
np
aspir
np
swab
midturbin
swab
place
viral
transport
media
oropharyng
swab
specimen
less
sensit
either
np
swab
np
wash
specimen
due
substanti
lower
level
viru
present
oropharynx
nasopharynx
howev
combin
use
nasaloropharyng
swab
enhanc
recoveri
avian
infl
uenza
sarscov
np
fl
ock
synthet
swab
use
lieu
tradit
synthet
np
swab
sinc
fl
ock
np
swab
yield
greater
recoveri
viral
pathogen
sensit
compar
np
wash
specimen
rate
posit
b
pertussi
realtim
pcr
shown
compar
specimen
collect
either
np
rayon
swab
aluminum
shaft
ami
gel
charcoal
np
fl
ock
swab
univers
transport
media
lower
respiratori
tract
lrt
sampl
appropri
viral
pathogen
c
pneumonia
pneumonia
l
pneumophila
bacteri
pathogen
includ
induc
sputum
bronchial
alveolar
lavag
bronchial
wash
protect
brush
combicath
specimen
studi
examin
detect
flua
found
serious
ill
patient
requir
intens
care
upper
respiratori
tract
sampl
neg
lrt
sampl
posit
addit
factor
infl
uenc
pathogen
recoveri
includ
time
sampl
collect
onset
clinic
symptom
age
patient
children
tend
shed
higher
titer
viru
longer
period
time
adult
therefor
optim
detect
sampl
collect
within
day
adult
within
day
children
onset
symptom
sampl
transport
laboratori
soon
possibl
preferenti
wet
ice
refriger
test
perform
within
h
test
delay
sampl
store
multipl
freezethaw
avoid
process
decreas
pathogen
titer
target
lysi
stabil
matrix
prevent
target
degrad
deoxyribonucleas
dnase
andor
ribonucleas
rnase
follow
isol
purifi
cation
nucleic
acid
na
essenti
critic
step
everi
naat
particularli
import
respiratori
sampl
highli
viscou
contain
inhibitori
substanc
enzym
destroy
target
na
sampl
type
may
requir
pretreat
proteinas
k
similar
enzym
highli
effi
cient
commerci
na
extract
system
ensur
suffi
cient
na
recoveri
remov
inhibitori
substanc
could
result
ineffi
cient
amplifi
cation
target
na
present
major
na
extract
system
use
chaotrop
agent
lyse
viral
particl
bacteri
cell
silica
particl
membran
captur
releas
na
seri
wash
step
remov
inhibitori
substanc
na
gener
elut
either
rnase
dnase
free
water
stabil
buffer
edtatri
although
na
extract
perform
manual
use
exampl
spin
column
major
laboratori
current
use
autom
platform
extract
one
sampl
time
sampl
microwel
plate
format
mani
naat
fdaclear
specifi
c
extract
platform
method
laboratori
awar
substitut
anoth
extract
platform
method
constitut
major
chang
assay
protocol
regulatori
perspect
extract
procedur
modifi
ed
chang
entir
test
consid
ldt
laboratori
must
compliant
applic
state
feder
clia
standard
may
choos
compli
colleg
american
pathologist
regul
meet
state
feder
regulatori
requir
mani
amplifi
cation
detect
method
use
current
fdaclear
assay
tabl
addit
assay
fda
clear
may
ce
mark
use
vitro
diagnost
devic
ivd
europ
tabl
amplifi
cation
method
includ
tradit
revers
transcript
polymeras
chain
reaction
rtpcr
pcr
realtim
rtpcr
pcr
rtpcr
primer
extens
nest
pcr
amplicon
rescu
multiplex
pcr
armpcr
isotherm
amplifi
cation
nucleic
acid
sequenc
base
amplifi
cation
nasba
helicasedepend
amplifi
cation
nick
enzym
amplifi
cation
reaction
near
loop
mediat
amplifi
cation
lamp
primer
set
broad
rang
eg
famili
short
rang
eg
genu
pathogenspecifi
c
eg
genu
speci
target
may
singl
multipl
copi
includ
genom
rna
dna
messeng
rna
detect
technolog
util
fl
uorogen
intercal
dye
fl
uorogen
probe
taqman
fl
uoresc
reson
energi
transfer
fret
hydrid
molecular
beacon
scorpion
lock
nucleic
acid
lna
array
liquid
bead
gold
nanoparticl
solid
chip
electrochemicalbas
method
melt
curv
analysi
later
fl
ow
simpl
turbid
test
vari
consider
number
target
detect
rang
one
pathogen
target
plu
intern
control
ic
target
plu
ic
differ
target
detect
viral
andor
bacteri
test
abl
detect
differenti
variou
type
within
viru
famili
eg
tabl
platform
inclus
na
extract
amplifi
cation
detect
perform
one
cartridg
eg
genexpert
cepheid
sunnyval
ca
coba
liat
system
roch
molecular
systemsiquum
marlborough
one
pouch
film
array
salt
lake
citi
ut
one
chamber
multitest
wheel
cartridg
simplexa
direct
focu
diagnost
cypress
ca
test
perform
use
modular
system
incorpor
na
extract
amplifi
cation
separ
unit
detect
eg
verigen
nanospher
northbrook
il
modular
system
separ
isol
amplifi
cation
combin
detect
simplexa
focu
diagnost
proflu
genprob
san
diego
ca
lyra
quidel
san
diego
ca
system
isol
amplifi
cation
detect
perform
separ
xtag
rvp
luminex
austin
tx
esensor
system
genmark
diagnost
carlsbad
ca
infi
niti
rvp
plu
autogenom
vista
ca
resplex
ii
qiagen
valencia
ca
limit
number
test
fdaclear
detect
bacteri
pathogen
one
highli
multiplex
test
filmarray
respiratori
panel
test
viral
pathogen
three
bacteri
pathogen
c
pneumonia
pneumonia
b
pertussi
one
addit
assay
fdaclear
detect
pneumonia
illumi
gene
mycoplasma
assay
meridian
bioscienc
inc
cincinnati
oh
two
addit
assay
fdaclear
detect
b
pertussi
illumi
gene
pertussi
assay
meridian
amplivu
bordetella
assay
quidel
san
diego
ca
timetoresult
fdaclear
assay
rang
min
approxim
h
depend
platform
rapid
result
h
allinclus
cartridgepouch
base
test
technic
handson
time
vari
min
approxim
h
current
naat
rate
clia
moder
high
complex
januari
fi
rst
waiv
naat
clia
clear
fda
aler
infl
uenza
b
test
aler
scarborough
scarborough
perform
test
sampl
receiv
test
base
insert
aler
instrument
aler
min
heat
step
sampl
elut
nasal
collect
swab
directli
sampl
receiv
buffer
transfer
cartridg
use
transfer
sampl
test
cartridg
nearamplifi
cation
detect
occur
approxim
min
comprehens
diagnosi
cap
rapidli
identifi
pathogen
associ
hap
vap
addit
test
need
target
main
bacteri
pathogen
research
use
ruo
unyvero
system
cureti
stutgart
gr
assay
develop
aid
diagnosi
bacteri
pneumonia
specimen
preprocess
unyvero
lysat
ad
assayspecifi
c
cartridg
insert
unyvero
analys
step
control
unyvero
cockpit
assay
detect
major
bacteri
pathogen
acinetobact
baumanii
enterobact
spp
escherichia
coli
klebsiella
oxytoca
klebsiella
pneumonia
haemophilu
infl
uenza
moraxella
catarrhali
morganella
morganii
proteu
spp
aureu
pseudomona
aeruginosa
serratia
marcescen
maltophilia
pneumonia
atyp
pathogen
c
pneumonia
l
pneumophila
one
fungal
pathogen
pneumocysti
jiroveci
known
caus
cap
hap
vap
addit
assay
detect
gene
associ
major
categori
antibiot
resist
timetoresult
approxim
h
assay
serv
preliminari
screen
follow
cultur
tradit
antimicrobi
suscept
test
preliminari
studi
demonstr
assay
detect
pathogen
routin
cultur
unyvero
system
detect
numer
resist
marker
allow
chang
empir
antibiot
therapi
within
h
patient
test
ruo
abbott
plexid
system
abbott
abbott
park
il
compris
broad
rang
pcr
rtpcr
electrospray
ioniz
mass
spectrometri
pcresim
pathogen
detect
follow
na
extract
pcr
andor
rtpcr
perform
microwel
plate
use
multipl
primer
pair
one
primer
set
per
well
follow
amplifi
cation
autom
platform
perform
postpcr
desalt
purifi
cation
highresolut
mass
spectrometri
use
esim
raw
spectra
analyz
calibr
intern
mass
standard
spectral
analysi
determin
nucleotid
base
composit
singlestrand
oligonucleotid
complementari
initi
target
evalu
rel
concentr
target
target
present
semiquantit
valu
obtain
compar
peak
height
intern
pcr
calibr
intern
mass
standard
present
everi
well
initi
plexid
ibi
system
replac
abbott
iridica
ruo
system
abbott
compris
plexid
sp
nucleic
acid
extract
platform
plexid
fh
liquid
handler
assay
setup
new
version
plexid
pcresim
platform
timetoresult
h
pcror
rtpcresim
use
detect
identifi
varieti
respiratori
virus
infl
uenza
subtyp
bacteria
fungi
associ
rti
huttner
et
al
overal
naat
respiratori
viral
atyp
bacteri
pathogen
highli
sensit
specifi
c
sampl
collect
shortli
onset
clinic
symptom
see
refer
tabl
assay
detect
mix
infect
broad
rang
viral
type
within
famili
perform
result
clinic
trial
fda
clearanc
investigatoriniti
studi
need
review
care
evalu
assay
mani
factor
affect
overal
result
patient
popul
age
test
condit
specimen
collect
factor
storag
time
sampl
collect
test
compar
method
use
analysi
similarli
result
obtain
differ
studi
vari
signifi
cantli
assay
target
depend
studi
design
see
refer
tabl
numer
studi
demonstr
target
within
particular
assay
detect
sensit
naat
also
certain
limit
due
complex
primer
probe
design
interact
highli
multiplex
naat
sometim
less
sensit
individu
naat
reduc
analyt
sensit
howev
alway
correl
reduc
clinic
sensit
sinc
viral
quantiti
clinic
sampl
depend
viru
time
sampl
collect
often
much
higher
limit
detect
assay
naat
often
less
sensit
virus
multipl
serotyp
adv
decreas
perform
detect
adv
clinic
signifi
cant
particularli
test
sampl
immunosuppress
patient
eg
transplant
patient
adv
infect
high
mortal
rate
treat
highrisk
patient
laboratori
may
elect
supplement
test
either
sensit
broadli
reactiv
advspecifi
c
assay
cell
cultur
mani
assay
distinguish
hrv
ev
due
fact
assay
target
utr
genet
similar
two
virus
perform
assay
particular
rna
virus
also
may
affect
sequenc
mutat
occur
time
mutat
result
primerprob
mismatch
decreas
assay
sensit
result
total
lack
target
amplifi
cation
detect
result
cross
reactiv
modifi
cation
assay
accommod
genet
chang
would
clear
fda
highli
multiplex
assay
revalid
requir
extens
assess
target
interact
thu
make
chang
extrem
diffi
cult
fdaclear
assay
detect
b
pertussi
target
multicopi
gene
gene
found
b
pertussi
copiescel
also
b
holmseii
copiescel
strain
b
brochioseptica
therefor
assay
specif
b
pertussi
altern
target
must
test
differenti
three
speci
also
detect
b
parapertussi
addit
pseudooutbreak
pertussi
describ
indic
great
caution
must
use
perform
naat
also
collect
test
sampl
particularli
area
vaccin
administ
final
due
short
time
local
atyp
bacteri
pathogen
urt
detect
pathogen
may
requir
combin
variou
sampl
type
variou
test
method
includ
naat
serolog
antigen
test
provid
sensit
result
advantag
naat
compar
tradit
test
method
includ
improv
sensit
need
viabl
organ
detect
broader
scope
pathogen
identifi
ed
abil
detect
mix
infect
advantag
also
rais
issu
interpret
result
recent
detect
respiratori
viru
consid
signifi
cant
sever
studi
shown
respiratori
virus
detect
asymptomat
patient
one
studi
found
naat
identifi
ed
viru
specimen
symptomat
children
also
detect
viru
specimen
children
without
symptom
anoth
studi
demonstr
similar
colon
cov
symptomat
hospit
children
versu
asymptomat
outpati
control
popul
overal
preval
cov
type
cov
signifi
cantli
higher
among
hospit
children
control
respiratori
virus
np
swab
identifi
ed
asymptomat
symptomat
solid
organ
transplant
recipi
earli
transplant
data
suggest
due
high
preval
posit
result
children
immunocompromis
patient
without
symptom
result
interpret
cautious
context
clinic
present
radiograph
fi
nding
laboratori
test
addit
clinician
must
awar
naat
detect
nucleic
acid
linger
previou
infect
sampl
submit
assess
therapeut
respons
may
remain
posit
day
week
treatment
due
presenc
nonviabl
organ
due
treatment
failur
situat
cultur
quantit
naat
see
futur
direct
may
provid
best
option
increas
use
highli
multiplex
respiratori
viru
assay
varieti
mix
viral
infect
detect
clinic
import
viru
alway
evid
nonviabl
viru
previou
infect
may
detect
make
imposs
determin
virus
contribut
current
ill
test
report
need
explain
virus
includ
naat
panel
sensit
specifi
citi
test
neg
result
preclud
infect
specifi
c
pathogen
due
mani
factor
lead
decreas
assay
sensit
asid
detect
atyp
pathogen
bordetella
spp
detect
bacteri
pathogen
includ
unyvero
test
directli
clinic
sampl
rais
sever
interest
question
need
address
differenti
colon
infect
promot
overus
antibiot
quantit
assay
necessari
assay
cut
valu
establish
clinic
relev
threshold
mani
pathogen
need
includ
screen
test
detect
broad
scope
potenti
gramposit
gramneg
bacteri
pathogen
limit
multiplex
capabl
assay
detect
minimum
pathogen
highest
clinic
impact
diffi
cult
treat
detect
broad
rang
resist
mechan
genet
marker
porin
downregul
pseudomona
spp
trust
posit
result
direct
antibiot
therapi
trust
neg
result
possibl
presenc
unknown
resist
mechan
need
link
resist
marker
specifi
c
bacteri
target
exampl
interpret
result
posit
specifi
c
resist
gene
detect
organ
would
resid
type
test
provid
action
result
ie
chang
clinic
practic
answer
question
resolv
clinic
trial
compar
naat
result
classic
microbiolog
test
clinic
practic
patient
outcom
howev
futur
test
may
combin
multiplex
naat
viral
bacteri
screen
laboratori
must
consid
multipl
factor
select
appropri
naat
develop
test
algorithm
tabl
consider
includ
patient
popul
fda
statu
naat
implic
regulatori
issu
platform
type
test
complex
technic
expertis
requir
turnaround
time
test
volum
batch
vs
singl
unit
test
number
type
pathogen
detect
higher
cost
naat
easili
offset
replac
less
sensit
test
method
test
site
lieu
referr
refer
laboratori
addit
cost
offset
demonstr
benefi
ts
improv
patient
care
fi
nancial
outcom
includ
reduct
antibiot
use
reduct
unnecessari
diagnost
test
procedur
reduct
hospit
day
achiev
benefi
ts
naat
perform
within
h
sampl
collect
result
avail
within
clinic
relev
time
frame
advent
singl
unit
cartridg
pouch
base
test
requir
minim
handson
time
minim
molecular
technic
expertis
size
laboratori
perform
naat
shift
consid
impact
global
travel
comprehens
highli
specifi
c
naat
perform
year
round
limit
specifi
c
season
although
posit
predict
valu
test
remain
high
time
low
viral
preval
laboratori
consid
confi
rmatori
test
viru
detect
unusu
time
period
pathogen
preval
specifi
c
group
eg
rsv
hmpv
children
elderli
limit
test
specifi
c
age
group
miss
clinic
relev
diseas
patient
popul
infect
pathogen
also
sometim
atyp
present
pericard
due
hmpv
otherwis
healthi
adult
therefor
age
may
use
triag
initi
test
govern
fi
nal
scope
virus
includ
diagnost
test
addit
step
wise
test
consid
base
risk
factor
age
immun
statu
coinfect
could
lead
seriou
nosocomi
transmiss
health
care
set
miss
unexpect
local
nation
intern
event
pandem
chang
test
algorithm
laboratori
must
prepar
adapt
quickli
event
kit
posit
neg
control
ic
extern
control
use
verifi
perform
reagent
ensur
inhibitori
substanc
remain
extract
could
lead
poor
amplifi
cation
reduc
assay
sensit
falseneg
result
control
test
accord
regulatori
requir
outlin
clia
cap
state
feder
regulatori
agenc
accord
manufactur
instruct
ideal
control
go
process
patient
sampl
ic
best
ad
na
extract
step
ensur
effi
cient
recoveri
na
ic
ad
extract
confi
rm
amplifi
cation
effi
cienci
extern
extract
control
must
use
unless
extract
method
demonstr
neglig
inhibit
gener
sampl
type
test
amplifi
cation
detect
ic
essenti
demonstr
lack
amplifi
cation
failur
decreas
effi
cienci
extern
posit
neg
control
provid
kit
must
use
verifi
new
lot
andor
shipment
reagent
analyt
multiplex
must
verifi
ed
individu
either
singl
reaction
compon
pool
control
daili
posit
individu
pool
neg
control
must
run
thereaft
batch
test
perform
rotat
control
lotship
valid
accept
test
use
singl
unit
cartridgepouch
contain
procedur
control
ic
process
control
requir
extern
control
run
individu
cartridgepouch
perform
procedur
control
verifi
ed
extern
posit
control
analyt
neg
control
requir
verifi
cation
new
lotship
minimum
per
month
laboratori
must
ensur
proper
procedur
prevent
sampl
amplicon
cross
contamin
could
caus
falseposit
result
laboratori
need
interpret
neg
result
ic
valu
context
presenc
absenc
potenti
nucleic
acid
degrad
amplif
inhibit
laboratori
respons
continu
assess
perform
assay
ensur
time
perform
declin
due
factor
genet
shift
target
analyt
final
ongo
assess
technic
compet
particip
profici
test
program
essenti
ensur
highqual
perform
result
viru
type
amount
viru
present
viral
load
signifi
cantli
impact
clinic
characterist
clinic
cours
rti
quantit
detect
viral
respiratori
pathogen
help
assess
dynam
viral
prolifer
better
understand
viral
pathogenesi
permit
mean
evalu
signifi
canc
coinfect
sinc
naat
detect
viabl
nonviabl
viru
monitor
patient
treatment
respons
qualit
test
provid
littl
inform
test
may
remain
posit
day
even
success
therapi
quantit
test
demonstr
declin
viral
load
therapi
accur
assess
patient
respons
fig
failur
see
declin
fig
would
potenti
indic
earlier
need
consid
altern
therapi
inform
especi
import
critic
ill
patient
immunosuppress
patient
final
viral
load
assay
provid
import
inform
assess
new
antivir
agent
fda
clinic
trial
futur
assay
develop
consid
quantifi
cation
viral
target
antivir
resist
neuraminidas
inhibitor
assess
phenotyp
genotyp
neuraminidas
inhibit
assay
detect
decreas
suscept
determin
inhibitori
concentr
ic
howev
assay
requir
growth
viru
presenc
quasispeci
lead
unreli
result
altern
genotyp
assay
easier
identifi
known
resist
mutat
howev
newli
identifi
ed
mutat
requir
phenotyp
confi
rmation
although
molecular
assay
fdaclear
infl
uenza
resist
test
sever
method
use
includ
tradit
sanger
sequenc
pyrosequenc
pcr
genotyp
assay
nextgener
sequenc
ng
pyrosequenc
current
method
choic
sinc
method
fast
high
throughput
sensit
detect
mutat
present
popul
assess
multipl
known
mutat
eg
mutat
found
resist
strain
well
unknown
mutat
polymorph
ng
ad
advantag
gener
longer
sequenc
length
identifi
ed
new
genet
mutat
associ
neuraminidas
resist
laboratori
consid
offer
resist
test
season
circul
strain
may
vari
resist
pattern
exampl
demonstr
variabl
oseltamivir
suscept
especi
patient
high
risk
develop
sever
diseas
eg
pregnant
immunosuppress
addit
screen
resist
indic
serious
ill
patient
continu
shed
viru
clinic
improv
prolong
antivir
therapi
last
decad
develop
ng
transform
laborintens
slow
process
realtim
method
applic
respiratori
diagnost
complex
ng
beyond
scope
chapter
use
ng
continu
evolv
clinic
laboratori
particularli
light
easytous
bench
top
sequenc
ion
torrent
person
genom
machin
pgm
life
technolog
carlsbad
ca
miseq
illumina
san
diego
ca
alreadi
ng
use
detect
identifi
respiratori
pathogen
resist
pathogen
marker
genet
character
virus
explor
respiratori
microbiom
understand
epidemiolog
respiratori
pathogen
new
emerg
technolog
simpl
method
perform
requir
bioinformat
test
increasingli
becom
part
routin
diagnost
idsa
diagnost
task
forc
report
better
test
better
care
improv
diagnost
infecti
diseas
highlight
import
diagnost
test
manag
infecti
diseas
likewis
cdc
report
antibiot
resist
threat
us
state
develop
new
drug
new
diagnost
essenti
combat
threat
multipledrugresist
pathogen
incorpor
naat
routin
practic
diagnosi
infecti
diseas
continu
grow
bring
new
advanc
technolog
allow
rapid
accur
detect
viral
bacteri
fungal
respiratori
pathogen
